Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ravish H S, Akash Khobragade, Durga Satapathy, Monica Gupta, Surendra Kumar, Vinay Bhomia, Ramasubramanian V, Maharshi Desai & Ashok Dilipkumar Agrawal. (2021) Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study. Human Vaccines & Immunotherapeutics 17:11, pages 4239-4245.
Read now
Read now
Terapong Tantawichien & Charles E. Rupprecht. (2020) Modern biologics for rabies prophylaxis and the elimination of human cases mediated by dogs. Expert Opinion on Biological Therapy 20:11, pages 1347-1359.
Read now
Read now
Scott Preiss, Pornthep Chanthavanich, Lin H. Chen, Cinzia Marano, Philippe Buchy, Rosa van Hoorn, Marije Vonk Noordegraaf & Piyali Mukherjee. (2018) Post-exposure prophylaxis (PEP) for rabies with purified chick embryo cell vaccine: a systematic literature review and meta-analysis. Expert Review of Vaccines 17:6, pages 525-545.
Read now
Read now
Charles E. Rupprecht, Thirumeni Nagarajan & Hildegund Ertl. (2016) Current Status and Development of Vaccines and Other Biologics for Human Rabies Prevention. Expert Review of Vaccines 15:6, pages 731-749.
Read now
Read now
Articles from other publishers (20)
Charles E. Rupprecht & Hildegund C.J. Ertl. 2023. Plotkin's Vaccines. Plotkin's Vaccines
969
997.e13
.
Beatriz P. Quiambao, Jonathan G. Lim, Valerie Bosch Castells, Christele Augard, Celine Petit, Catherine Bravo, Valentine Delore & Guy Houillon. (2022) One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess immunogenicity and safety. Vaccine 40:36, pages 5347-5355.
Crossref
Crossref
Beatriz Quiambao, Cecilia Montalban, Ada-Maria Minutello, Françoise Guinet-Morlot, Annick Moureau, Celine Petit & Sylvie Pichon. (2022) Serum-free purified Vero rabies vaccine is safe and immunogenic in children: Results of a randomized phase II pre-exposure prophylaxis regimen study. Vaccine 40:35, pages 5170-5178.
Crossref
Crossref
Sylvie Pichon, Annick Moureau, Celine Petit, L. Chu, B. Essink, D. Muse, J. Saleh, Françoise Guinet-Morlot & Ada-Maria Minutello. (2022) Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study. Vaccine.
Crossref
Crossref
Atul Kakar, Atul Gogia, Sanjay Kumar Solanki, Arjit Jadiya & Deepika Singh. (2021) Safety and immunogenicity of SURE RAB™, an inactivated cell culture derived rabies vaccine: A comparative, phase III clinical trial. Indian Journal of Medical Microbiology 39:1, pages 63-66.
Crossref
Crossref
Thomas Moulenat, Céline Petit, Valérie Bosch Castells & Guy Houillon. (2020) Purified Vero Cell Rabies Vaccine (PVRV, Verorab®): A Systematic Review of Intradermal Use Between 1985 and 2019. Tropical Medicine and Infectious Disease 5:1, pages 40.
Crossref
Crossref
Hildegund C. J. Ertl. 2020. Rabies and Rabies Vaccines. Rabies and Rabies Vaccines
155
180
.
Tineke Cantaert, Laurence Borand, Lauriane Kergoat, Chanthy Leng, Sivlin Ung, Sotheary In, Yiksing Peng, Chandara Phoeun, Chanthy Hing, Chun Navy Taing, Manil Saman, Sivuth Ong, Channa Mey, Rithy Choeung, Sowath Ly, Philippe Dussart, Hervé Bourhy & Arnaud Tarantola. (2019) A 1-week intradermal dose-sparing regimen for rabies post-exposure prophylaxis (RESIST-2): an observational cohort study. The Lancet Infectious Diseases 19:12, pages 1355-1362.
Crossref
Crossref
Amrita Pattanaik & Reeta S. Mani. (2019) WHOʼs new rabies recommendations. Current Opinion in Infectious Diseases 32:5, pages 401-406.
Crossref
Crossref
Joss Kessels, Arnaud Tarantola, Naseem Salahuddin, Lucille Blumberg & Lea Knopf. (2019) Rabies post-exposure prophylaxis: A systematic review on abridged vaccination schedules and the effect of changing administration routes during a single course. Vaccine 37, pages A107-A117.
Crossref
Crossref
Martine Denis, Ivana Knezevic, Henry Wilde, Thiravat Hemachudha, Deborah Briggs & Lea Knopf. (2019) An overview of the immunogenicity and effectiveness of current human rabies vaccines administered by intradermal route. Vaccine 37, pages A99-A106.
Crossref
Crossref
Katie Hampson, Bernadette Abela-Ridder, Omesh Bharti, Lea Knopf, Monique Léchenne, Rolande Mindekem, Arnaud Tarantola, Jakob Zinsstag & Caroline Trotter. (2019) Modelling to inform prophylaxis regimens to prevent human rabies. Vaccine 37, pages A166-A173.
Crossref
Crossref
Arnaud Tarantola, Mathurin Cyrille Tejiokem & Deborah J. Briggs. (2019) Evaluating new rabies post-exposure prophylaxis (PEP) regimens or vaccines. Vaccine 37, pages A88-A93.
Crossref
Crossref
Arnaud Tarantola, Sowath Ly, Malen Chan, Sotheary In, Yiksing Peng, Chanthy Hing, Chun Navy Taing, Chandara Phoen, Sovann Ly, Simon Cauchemez, Philippe Buchy, Philippe Dussart, Hervé Bourhy & Jean-Yves Mary. (2019) Intradermal rabies post-exposure prophylaxis can be abridged with no measurable impact on clinical outcome in Cambodia, 2003–2014. Vaccine 37, pages A118-A127.
Crossref
Crossref
Beatriz P. Quiambao, Cristina Ambas, Sherylle Diego, Valérie Bosch Castells, Joanna Korejwo, Céline Petit & Guy Houillon. (2019) Intradermal post-exposure rabies vaccination with purified Vero cell rabies vaccine: Comparison of a one-week, 4-site regimen versus updated Thai Red Cross regimen in a randomized non-inferiority trial in the Philippines. Vaccine 37:16, pages 2268-2277.
Crossref
Crossref
M.J. Warrell. (2019) Rabies post-exposure vaccination in 2 visits within a week: A 4-site intradermal regimen. Vaccine 37:9, pages 1131-1136.
Crossref
Crossref
Phirangkul Kerdpanich, Pornthep Chanthavanich, Mari Rose De Los Reyes, Jodor Lim, Delia Yu, Ma. Cecilia Ama, Zenaida Mojares, Daniela Casula, Ashwani Kumar Arora & Michele Pellegrini. (2018) Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults. PLOS Neglected Tropical Diseases 12:6, pages e0006340.
Crossref
Crossref
Günther Slesak, Ralf Fleck, Helmut Scherbaum, Gunnar Blumenstock & Johannes Schäfer. (2018) Adverse events in vaccinations for travelers – a 1-year prospective survey in a travel clinic in Germany. Journal of Travel Medicine 25:1.
Crossref
Crossref
Charles E. Rupprecht, Thirumeni Nagarajan & Hildegund Ertl. 2018. Plotkin's Vaccines. Plotkin's Vaccines
918
942.e12
.
Philippe Buchy, Scott Preiss, Ved Singh & Piyali Mukherjee. (2017) Heterogeneity of Rabies Vaccination Recommendations across Asia. Tropical Medicine and Infectious Disease 2:3, pages 23.
Crossref
Crossref